(Total Views: 781)
Posted On: 08/20/2020 10:16:12 PM
Post# of 153966
Re: invisioner #50986
Awesome, any association with JAMA and other industry stalwarts can only increase leronlimab's credibility with journalists.
I looked through JAMAs twitter feed and I think I figured out the tweet. They had Dr. Redfield of the CDC on their JAMA LIVE webcast today and this was a question submitted by the audience to ask during the interview.
JAMA is responding that the CDC doesn't really focus on new drugs, which is true as that's the FDAs responsibility, so they didn't ask Dr. Redfield but they'll forward it to the CDC anyways. And then JAMA provides a link to their clinical trial tracker where you can find both Leronlimab COVID trials being tracked. https://covid-trials.org/
I looked through JAMAs twitter feed and I think I figured out the tweet. They had Dr. Redfield of the CDC on their JAMA LIVE webcast today and this was a question submitted by the audience to ask during the interview.
JAMA is responding that the CDC doesn't really focus on new drugs, which is true as that's the FDAs responsibility, so they didn't ask Dr. Redfield but they'll forward it to the CDC anyways. And then JAMA provides a link to their clinical trial tracker where you can find both Leronlimab COVID trials being tracked. https://covid-trials.org/
(2)
(0)
